- Home
- RIGL vs SMBK Comparison
RIGL vs SMBK Comparison
Compare RIGL & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | SMBK |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 636.5M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | SMBK |
|---|---|---|
| Price | $49.33 | $37.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $43.20 | $38.63 |
| AVG Volume (30 Days) | ★ 638.4K | 67.1K |
| Earning Date | 11-04-2025 | 01-20-2026 |
| Dividend Yield | N/A | ★ 0.86% |
| EPS Growth | ★ 2698.26 | 41.99 |
| EPS | ★ 6.20 | 2.74 |
| Revenue | ★ $282,076,000.00 | $188,204,000.00 |
| Revenue This Year | $65.53 | $22.08 |
| Revenue Next Year | $0.22 | $9.89 |
| P/E Ratio | ★ $7.89 | $13.56 |
| Revenue Growth | ★ 79.13 | 18.22 |
| 52 Week Low | $14.63 | $26.31 |
| 52 Week High | $52.24 | $37.92 |
Technical Indicators
Market Signals| Indicator | RIGL | SMBK |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 62.95 |
| Support Level | $43.81 | $36.41 |
| Resistance Level | $52.24 | $37.65 |
| Average True Range (ATR) | 3.35 | 0.83 |
| MACD | -0.13 | 0.19 |
| Stochastic Oscillator | 75.13 | 85.69 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.